Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Farma-Tek Ilac San. Ve Tic v. Dermik Laboratories

March 31, 2011

FARMA-TEK ILAC SAN. VE TIC
LTD. STI
v.
DERMIK LABORATORIES, SANOFI-AVENTIS LLC USA, SANOFI-AVENTIS
U.S. INC.



The opinion of the court was delivered by: Ludwig, J.

MEMORANDUM

Defendants Dermik Laboratories, et al. move to dismiss this action because of forum non conveniens. Fed. R. Civ. P. 12(b)(3). The motion will be granted subject to conditions set out in the accompanying order. Defendants' motion to dismiss for failure to state a claim, Fed. R. Civ. P. 12(b)(6), will be denied as moot. Jurisdiction is diversity. 28 U.S.C. § 1332.

This action involves a dispute as to the right to register, market, and sell in Turkey two pharmaceutical products owned and manufactured in Canada by defendant Dermik Laboratories -- Benzamycin® and BenzaClin®. Plaintiff Farma-Tek la Sanayi Ve Tic Ltd. ti is a citizen of the Republic of Turkey. The complaint filed August 13, 2009, as amended January 4, 2010, alleges breach of contract, promissory estoppel, unjust enrichment, and tortious interference with plaintiff's existing and prospective contracts in Turkey. It asks for a declaration of plaintiff's right to distribute the products in Turkey.

Farma-Tek's operations are entirely within Turkey. Sanofi-aventis U.S. LLC, a Delaware company, and sanofi-aventis U.S. Inc., a Delaware corporation, each has its principal place of business in Bridgewater, New Jersey. In January 2006, Dermik's assets were transferred to sanofi-aventis U.S. LLC, which manages the marketing and sale of both products from that location.

In 1997, Farma-Tek and Dermik entered into a "Distribution Agreement" that granted Farma-Tek exclusive rights to market, distribute, and sell Benzamycin® in Turkey for a five-year term ending December 25, 2002.*fn1 The Agreement states that it "will be construed in accordance with the law of the United States and . . . Pennsylvania" and "may not be altered or modified, nor may any term be waived in whole or in part, except in writing signed by duly authorized representatives of the parties."*fn2

According to Farma-Tek, the Agreement was modified by the parties' course of conduct and by oral promises given by Dermik that Farma-Tek would be the exclusive distributor of Benzamycin® and BenzaClin® in Turkey. Farma-Tek relies on two certificates of authority and a power of attorney signed by Dermik and filed by Farma-Tek with the Turkish Ministry of Health in 2002 and 2007. These documents certify plaintiff's rights to register Benzamycin® and BenzaClin® and authorize "[Farma-Tek] to represent Dermik Laboratories vis-a-vis the Health Authority in Turkey with respect to all registration, marketing authorization and licensing . . . related procedures."*fn3 Farma-Tek asserts that under the Turkish Ministry of Health's regulations relating to medicinal products and standard business practices, the documents evidence the parties' intent to modify the Agreement. In Farma-Tek's view, the documents expanded the scope of its distribution rights to include both products and also renewed the term of distribution for two successive five-year periods to July 15, 2012.*fn4

Defendants' response: Under the documents, plaintiff had no right or authority to distribute BenzaClin®. Moreover, after the Agreement ended on December 25, 2002, defendants considered it to be terminable at will. By letter of June 8, 2009, Dermik notified Farma-Tek that their business relationship would terminate effective December 31, 2009. As a result, plaintiff became contractually obligated to return the licenses and permits issued by the Ministry of Health for distribution of Benzamycin® and BenzaClin®. Plaintiff refuses to return them.

On May 10, 2010, defendants sued Farma-Tek in the Kadikoy 4th Commercial Court of First Instance in Istanbul, where Farma-Tek's principal office is located, to obtain an order that their Agreement was terminated and directing Farma-Tek to return the licenses and permits to Dermik.*fn5 Under Turkish law, the Ministry of Health appears to require an order from a Turkish court before record ownership of a product may be transferred.*fn6

Piper Aircraft Co. v. Reyno, 454 U.S. 235 (1981) and Gulph Oil Corp. v. Gilbert, 330 U.S. 501 (1947) set forth the law of forum non conveniens. Accord: Windt v. Qwest Commc'n Int'l, Inc., 529 F.3d 183, 189 (3d Cir. 2008). Although "a plaintiff's choice of forum should rarely be disturbed," Reyno, 454 U.S. at 241, a court "may resist imposition upon its jurisdiction even when jurisdiction is authorized by the letter of a general venue statute." Gilbert, 330 U.S. at 507. When a foreign plaintiff selects a forum other than its home, the strong presumption in favor of plaintiff's choice loses much force. "'Because the central purpose of any forum non conveniens inquiry is to ensure that the trial is convenient, a foreign plaintiff's choice deserves less deference.'" Windt, 529 F.3d at 190 (quoting Reyno, 454 U.S. at 255-56).

In evaluating a forum non conveniens motion, a balancing of the following private and public interest factors is prescribed:

[T]he private interests of the litigants include . . . relative ease of access to sources of proof; availability of compulsory process for attendance of . . . witnesses . . . and all other practical problems that make trial of a case easy, expeditious and inexpensive. There may also be questions as to the enforceability of a judgment if one is obtained.

Factors of public interest also have place in applying the doctrine [of forum non conveniens]. Administrative difficulties follow for courts when litigation is piled up in congested centers instead of being handled at its origin. Jury duty is a burden that ought not to be imposed upon the people of a community which has no relation to the litigation. . . . There is a local interest in having localized controversies decided at home. There is an appropriateness, too, in having the trial of a diversity case in a forum that is at home with the state law that must govern the case, rather than having a court in some other forum untangle problems in conflict of laws, and in law foreign to itself.

Gilbert, 330 U.S. at 508-09; accord: Windt, 529 F.3d at 189.

Turkey's court system constitutes a fully adequate forum. Plaintiff's opposition does not suggest otherwise. There are no service of process issues in Turkey, and defendants have ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.